BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire October 03, 2025 PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on October 2, 2025, the compensation committee of BridgeBio's board […]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire October 03, 2025 NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company granted inducement awards to purchase up to 138,900 shares of common stock
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025 GlobeNewswire October 03, 2025 October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of shareholders will be
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire October 03, 2025 CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new employees under
BAB, Inc. Reports Results for 3rd Quarter FY 2025 GlobeNewswire October 03, 2025 DEERFIELD, Ill., Oct. 03, 2025 (GLOBE NEWSWIRE) — BAB, Inc. (OTCQB: BABB), announced its financial results for the third quarter ended August 31, 2025. For the quarter ended August 31, 2025 BAB had revenues of $769,000 and net income of $168,000, or
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on October 1, 2025, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 84,750 shares of Curis
News report from GDToday. As the world in 2025 commemorates the 80th anniversary of victory in the War of Resistance Against Japanese Aggression, the bond forged between Chinese and American servicemen duringWWII is brought into renewed focus. Today, with only a handful of centenarian veterans left-one from China and one from the United States-their recent
(NASDAQ:ARQT), WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,500 restricted stock units of Arcutis' common stock to 12 newly hired employees. These awards were approved by the Compensation Committee
(NASDAQ:FHB), HONOLULU, Oct. 03, 2025 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its third quarter 2025 financial results on Friday, October 24, 2025 before the market opens. First Hawaiian will host a conference call to discuss the company's results on the same day at 1:00 p.m. Eastern
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire October 03, 2025 WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,500 restricted stock units of Arcutis' common stock